ReviewCurrent opinion in hematology2009
Molecular signatures in acute myeloid leukemia.
Review in Current opinion in hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis.Nature communications · 2024Article
- DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.Genome research · 2021Article
- Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.Blood advances · 2021Article
- Circular RNAs in Blood Malignancies.Frontiers in molecular biosciences · 2020Review
- Identification of novel lncRNAs involved in the pathogenesis of childhood acute lymphoblastic leukemia.Oncology letters · 2019Article
- Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.Journal of oncology · 2019Review
- [Outcome of acute myeloid leukemia with FLT3-ITD mutation treated by allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.Frontiers in oncology · 2017Review
- A Case Report of Concurrent IDH1 and NPM1 Mutations in a Novel t(X;2)(q28;p22) Translocation in Acute Myeloid Leukaemia without Maturation (AML-M1).The Malaysian journal of medical sciences : MJMS · 2015Article
- Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.Molecular cancer · 2015Article
- Genomic characterization of acute leukemias.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2014Review
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.Nature reviews. Clinical oncology · 2012Review
- Using bioinformatic approaches to identify pathways targeted by human leukemogens.International journal of environmental research and public health · 2012Article
- Cancer stem cells: an evolving concept.Nature reviews. Cancer · 2012Review
- An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.Seminars in oncology · 2011Review
- Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.Genes & cancer · 2011Article
- Article
- The role of microRNAs in acute myeloid leukemia.F1000 biology reports · 2010Article
- Article
- The role of molecular tests in acute myelogenous leukemia treatment decisions.Current hematologic malignancy reports · 2010Review
Corrections and comments
- Commented on byMyeloid disease.2009
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewAcute myeloid leukemia (AML) is characterized by a high degree of heterogeneity with respect to chromosome abnormalities, gene mutations and changes in expression of multiple genes and microRNAs. In this article, we review the results of recent studies of AML that used microarray-based genome-wide gene-expression and microRNA-expression profiling. RECENT
findingsGenome-wide analyses of gene expression and microRNA expression have revealed AML signatures that are closely associated with some, but not all, cytogenetic and molecular genetic subsets, helped in identification of novel biologic subtypes and led to characterization of molecular pathways involved in leukemogenesis. For some AML categories, namely core-binding factor AML and/or cytogenetically normal AML, gene-expression and microRNA-expression profiling provided prognostic information additional to that obtained from cytogenetics and analyses of gene mutations and single gene expression changes. SUMMARY: Gene-expression and microRNA-expression profiling not only has the potential to enhance our understanding of the disease biology, but also appears to constitute an applicable approach for outcome prediction and identification of novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.